Cel Sci (CVM) Long-Term Deferred Tax (2016 - 2025)
Cel Sci (CVM) posted Long-Term Deferred Tax of $65.9 million for Q3 2025, up 2.03% sequentially from $64.6 million in Q3 2024, and up 2.03% YoY from $64.6 million in Q3 2024.
Cel Sci (CVM) Long-Term Deferred Tax (2016 - 2025) Analysis & Trends
Cel Sci has reported Long-Term Deferred Tax for 8 years, with the latest figure at $65.9 million in Q3 2025.
- Quarterly Long-Term Deferred Tax rose 2.03% year-over-year to $65.9 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $65.9 million (up 2.03% YoY) and the FY2025 annual result came in at $65.9 million, up 2.03% from the prior year.
- Long-Term Deferred Tax improved to $65.9 million in Q3 2025 per CVM's latest filing, from $64.6 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $65.9 million in Q3 2025 and troughed at $30.8 million in Q3 2023.
- A 4-year average of $52.3 million and a median of $56.3 million in 2021 frame the typical range for Long-Term Deferred Tax.
- The sharpest annual moves came in 2024 and 2025: Long-Term Deferred Tax soared 109.54% in 2024, then climbed 2.03% in 2025.
- Over 4 years, Long-Term Deferred Tax stood at $48.1 million in 2021, then sank by 35.86% to $30.8 million in 2023, then surged by 109.54% to $64.6 million in 2024, then rose by 2.03% to $65.9 million in 2025.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $65.9 million, $64.6 million, and $30.8 million for Q3 2025, Q3 2024, and Q3 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Cel Sci | 2.13 Mn | -4.40 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 65.91 Mn |
| Sep 30, 2024 | 64.60 Mn |
| Sep 30, 2023 | 30.83 Mn |
| Sep 30, 2021 | 48.06 Mn |
| Sep 30, 2020 | 39.53 Mn |
| Sep 30, 2019 | 29.41 Mn |
| Sep 30, 2018 | 24.80 Mn |
| Sep 30, 2016 | 64.37 Mn |